contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pancreasuretm-demonstrates-88percent-sensitivity-and-98percent-specificity-in-interim-analysis-of-third-validation-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Immunovia operates in the biotechnology industry and focuses on the development of diagnostic tools for the early detection of cancer. The company's research and development is focused on molecular diagnostics and its products are aimed at healthcare institutions and physicians. The business is global with a strong presence in Europe and North America. Immunovia was founded in 2007 and is headquartered in Lund.

Immunovia

LUND - Immunovia AB (publ.), the pancreatic cancer diagnostics company, today announced results from a large international validation study, AFFIRM, demonstrating the accuracy of the PancreaSure...

<div class="mfn-preamble"><p><strong>LUND - Immunovia AB (publ.), the pancreatic cancer diagnostics company, today announced results from a large international validation study, AFFIRM, demonstrating the accuracy of the PancreaSure pancreatic cancer test in Stage 3-4 disease. In the study, PancreaSure detected cancer in 88.1% of blood samples from people with Stage 3 and 4 pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The PancreaSure test accurately classified 97.7% of samples from healthy individuals without cancer.</strong></p></div><div class="mfn-body"><p>“The PancreaSure test has now demonstrated excellent accuracy in three independent clinical studies,” said Jeff Borcherding, CEO of Immunovia. “PancreaSure is intended to detect early-stage pancreatic cancer in those at high risk for the disease, and the test showed strong performance in this target group in both the CLARITI and VERIFI studies. The AFFIRM study builds on these findings, reassuring physicians that PancreaSure can also detect late-stage disease and perform very well in healthy individuals.”</p><p>The AFFIRM study includes samples from six sites across Europe and the United States. Results released today represent an interim analysis of the study. Immunovia plans to expand the study with approximately 180 additional samples, with final results to be announced in the fourth quarter of 2025.</p><p>Separately, Immunovia is conducting studies to understand the impact of the PancreaSure test on physician decisions when screening high-risk individuals for pancreatic cancer. These decision-impact studies are an important component of the Company’s pursuit of reimbursement of the PancreaSure test by government payers and private insurers in the US.</p></div><div class="mfn-footer mfn-contacts mfn-0579f829bfb8"><p><strong class="mfn-heading-1">For further information, please contact</strong><br>Jeff Borcherding, CEO<br><a rel="noopener" href="mailto:jeff.borcherding@immunovia.com">jeff.borcherding@immunovia.com</a></p></div><div class="mfn-footer mfn-about mfn-efaf3745cec3"><p><strong class="mfn-heading-1">Immunovia in brief</strong><br>Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.<br>&nbsp;<br>USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.<br>&nbsp;<br>Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.<br>For more information, please visit <a rel="noopener" href="http://www.immunovia.com/">www.immunovia.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/a59b7e93-7c59-4956-abfa-302dc5fc297a/pancreasure-demonstrates-88-sensitivity-and-98-specificity-in-interim-analysis-of-third-validation-study.pdf" class="mfn-generated mfn-primary">PancreaSure™ Demonstrates 88% Sensitivity and 98% Specificity in Interim Analysis of Third Validation Study</a></p></div>

PancreaSure™ Demonstrates 88% Sensitivity and 98% Specificity in Interim Analysis of Third Validation Study